[1] Jager K J,Fraser S D S.The ascending rank of chronic kidney disease in the global burden of disease study[J].Nephrology Dialysis Translantation，2017,32(S2):i121-i128.
[2] Chen T K,Knicely D H,Grams M E.Chronic Kidney Disease Diagnosis and Management:A Review[J].JAMA,2019,322(13):1294-1304.
[3] Zhang L,Wang F,Wang L,et al.Prevalence of chronic kidney disease in China: a cross-sectional survey[J].Lancet,2012,379(9818):815-822.
[4] Glassock R J,Warnock D G,Delanaye P.The global burden of chronic kidney disease:estimates,
variability and pitfalls[J].Nature Reviews Nephrology，2017,13(2):104-114.
[5] Global,regional,and national age–sex specific all-cause and cause-specific mortality for 240 causes of death,1990–2013:a systematic analysis for the Global Burden of Disease Study 2013
[J].The Lancet,2015,385(9963):117-171.
[6] Djudjaj S,Boor P.Cellular and molecular mechanisms of kidney fibrosis[J]. Molecular Aspects of Medicine,2019,65:16-36.
[7] Dohi K.Echocardiographic assessment of cardiac structure and function in chronic renal disease[J].J Echocardiogr,2019,17(3):115-122.
[8] Quoc H T,Tam V,Thang H V.Plasma asymmetric dimethylarginine and its association with some of cardiovascular disease risk factors in chronic kidney disease[J]. Med J Malaysia,2019，
74(3):209-214.
[9] Tomlinson J A P，Caplin B，Borcuc Oet,et al.Reduced Renal Methylarginine Metabolism
Protects against Progressive Kidney Damage[J].Journal of the American Society of Nephrolog
-y,2015,26(12):3045-3059.
[10] Wang C,Jiang H,Jin J,et al.Development of Potent Type I Protein Arginine Methyltransferase
(PRMT) Inhibitors of Leukemia Cell Proliferation[J].Journal of Medicinal Chemistry,2017,
60 (21):8888-8905.
[11] Gessner A,Mieth M,Auge D,et al.Establishment of reference values for the lysine acetylation marker N?-acetyllysine in small volume human plasma samples by a multi-target LC–MS/MS method[J].Amino Acids,2019.
[12] Zinellu A, Sotgia S, Usai M F, et al. Improved method for plasma ADMA, SDMA, and arginine quantification by field-amplified sample injection capillary electrophoresis UV detection[J]. Anal Bioanal Chem,2011,399(5):1815-1821.
[13] Pecchini P, Malberti F, Mieth M, et al. Measuring asymmetric dimethylarginine (ADMA) in CKD:a comparison between enzyme-linked immunosorbent assay and liquid chromatography
electrospray tandem mass spectrometry[J].J Nephrol,2012,25(6):1016-1022.
[14] Rao P V L N, Bitla A. Simultaneous determination of arginine, citrulline, and asymmetric dimethylarginine in plasma by reverse-phase high-performance liquid chromatography[J]. Journal of Laboratory Physicians,2017,9(4):243.
[15] Alexander Bollenbach E H D T. Utility of homoarginine in the GC-MS quantification of asymmetric dimethylarginine (ADMA) in human serum proteins[J]. Analytical Biochemistry，
2018,563:67-70.
[16] Hartel N, Chew B, Qin J, et al. Deep protein methylation profiling by combined chemical and immunoaffinity approaches reveals novel PRMT1 targets[J]. Mol Cell Proteomics,2019.
[17] Quoc H T, Tam V, Thang H V. Plasma asymmetric dimethylarginine and its association with some of cardiovascular disease risk factors in chronic kidney disease[J]. Med J Malaysia,2019，
74(3):209-214.
[18] Gillis K, Stevens K K, Bell E, et al. Ascorbic acid lowers central blood pressure and asymmetric dimethylarginine in chronic kidney disease[J]. Clin Kidney J,2018,11(4):532-539.
[19] Tsikas D, Beckmann B, Gutzki F, et al. Simultaneous gas chromatography–tandem mass spectrometry quantification of symmetric and asymmetric dimethylarginine in human urine[J]. Analytical Biochemistry,2011,413(1):60-62.
[20] Bollenbach A, Huneau J, Mariotti F, et al. Asymmetric and Symmetric Protein Arginine Dimethylation: Concept and Postprandial Effects of High-Fat Protein Meals in Healthy Overweight Men[J]. Nutrients,2019,11(7):1463.
[21] Kuo H, Hsu C, Huang C, et al. Urinary arginine methylation index associated with ambulatory blood pressure abnormalities in children with chronic kidney disease[J]. Journal of the American Society of Hypertension,2012,6(6):385-392.
[22] Mihout F, Shweke N, Bigé N, et al. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis[J]. The Journal of Pathology,2011,223(1):37-45.
[23] Matsuguma K, Ueda S, Yamagishi S, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease[J]. J Am Soc Nephrol,2006,17(8):2176-2183.
[24] Wieczorek-Surdacka E, Hanff E, Chyrchel B, et al. Distinct associations between plasma osteoprotegerin, homoarginine and asymmetric dimethylarginine in chronic kidney disease male patients with coronary artery disease[J]. Amino Acids,2019,51(6):977-982.
[25] Isaivani Jayachandran S S P, Paramasivam B V S C, Subramanian M B V, et al. Association of circulatory asymmetric dimethylarginine (ADMA)[J]. Clincal Biochemistery, 2017,50(15):83
5-842.
[26] Malgorzewicz S, Heleniak Z, Lichodziejewska-Niemierko M, et al. Protein-energy wasting and asymmetric dimethylarginine in peritoneal dialysis patients[J]. Acta Biochim Pol,2018，
65(4):581-584.
[27] Quoc H T, Tam V, Thang H V. Plasma asymmetric dimethylarginine and its association with some of cardiovascular disease risk factors in chronic kidney disease[J]. Med J Malaysia,2019
74(3):209-214.
[28] Charytan D M, Padera R, Helfand A M, et al. Increased concentration of circulating angiogene
-sis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease[J]. Int J Cardiol,2014,176(1):99-109.
[29] Tomlinson J A, Caplin B, Boruc O, et al. Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage[J]. J Am Soc Nephrol,2015,26(12):3045-3059.
[30] Wu M, Lin P, Li L, et al. Reduced asymmetric dimethylarginine accumulation through inhibition of the type I protein arginine methyltransferases promotes renal fibrosis in obstructed kidneys[J]. The FASEB Journal,2019,33(6):6948-6956.
[31] Torino C, Pizzini P, Cutrupi S, et al. Vitamin D and methylarginines in chronic kidney disease (CKD)[J]. PLOS ONE,2017,12(10):e185449.
[32] Karahan S, Afsar B, Kanbay M. Ascorbic acid: a promising agent in chronic kidney disease?[J]. Clinical Kidney Journal,2018,11(4):530-531.
[33] Tain Y, Hsu C. Targeting on Asymmetric Dimethylarginine-Related Nitric Oxide-Reactive Oxygen Species Imbalance to Reprogram the Development of Hypertension[J].International Journal of Molecular Sciences,2016,17(12):2020.
[34] 夏嘉，陈文浩，高雅婵. 抗纤灵对慢性肾衰心脏病变小鼠NO、ADMA、NT-proBNP影响[J]. 辽宁中医药大学学报,2018,20(8):35-37.
[35] 吴洋洋. 温阳活血法治疗阳虚血瘀型3-4期CKD患者临床疗效观察及其对血清ADMA影响[D]. 福州:福建中医药大学,2016.
